These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30231453)

  • 1. Exploring Ethnic Differences in Toxicity in Early-Phase Clinical Trials for Oncology Drugs.
    Ogura T; Morita S; Yonemori K; Nonaka T; Urano T
    Ther Innov Regul Sci; 2014 Sep; 48(5):644-650. PubMed ID: 30231453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies.
    Corbaux P; El-Madani M; Tod M; Péron J; Maillet D; Lopez J; Freyer G; You B
    Eur J Cancer; 2019 Oct; 120():40-46. PubMed ID: 31479946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries.
    Maeda H; Kurokawa T
    Invest New Drugs; 2014 Aug; 32(4):661-9. PubMed ID: 24615632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
    Lee DP; Skolnik JM; Adamson PC
    J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring differences in drug doses between Japan and Western countries.
    Arnold FL; Kusama M; Ono S
    Clin Pharmacol Ther; 2010 Jun; 87(6):714-20. PubMed ID: 20410879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.
    Mizugaki H; Yamamoto N; Fujiwara Y; Nokihara H; Yamada Y; Tamura T
    J Clin Oncol; 2015 Jun; 33(18):2051-61. PubMed ID: 25918301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?
    Chiba K; Yoshitsugu H; Kyosaka Y; Iida S; Yoneyama K; Tanigawa T; Fukushima T; Hiraoka M
    J Clin Pharmacol; 2014 May; 54(5):483-94. PubMed ID: 24242979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated titration designs for phase I clinical trials in oncology.
    Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
    J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric phase I drug tolerance: a review and comparison of recent adult and pediatric phase I trials.
    Carlson L; Ho P; Smith M; Reisch J; Weitman S
    J Pediatr Hematol Oncol; 1996 Aug; 18(3):250-6. PubMed ID: 8689336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of the recommended phase 2 dose of molecular targeted agents.
    Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
    Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CPT-11: the European clinical development.
    Terret C; Couteau C; Armand JP
    J Infus Chemother; 1996; 6(3):152-7. PubMed ID: 9229329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early clinical trials in ECTG. Early Clinical Trial Group].
    Ogawa M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):238-41. PubMed ID: 8611053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of value of juvenile animal toxicity studies for supporting the safety of pediatric oncology phase I trials.
    Visalli T; Bower N; Kokate T; Andrews PA
    Regul Toxicol Pharmacol; 2018 Jul; 96():167-177. PubMed ID: 29763632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial/Ethnic composition of study participants in FDA-approved oncology new molecular entities, 2006-2008.
    Merenda C
    J Natl Med Assoc; 2012; 104(9-10):430-5. PubMed ID: 23342816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPT-11. The European experience.
    Armand JP; Terret C; Couteau C; Rixe O
    Ann N Y Acad Sci; 1996 Dec; 803():282-91. PubMed ID: 8993522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and insights of early phase oncology drug development in the Asia-Pacific region.
    Loong HH; Tan DSW; Shimizu T
    Chin Clin Oncol; 2019 Jun; 8(3):26. PubMed ID: 31311280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new model for determining the MTD during phase-I trials in pediatric oncology.
    Faivre C; Barbolosi D; Iliadis A
    Curr Top Med Chem; 2012; 12(15):1660-4. PubMed ID: 22978337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
    Buzdar AU; Holmes FA; Hortobagyi GN
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):101-4. PubMed ID: 7541151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.